Search the Community
Showing results for tags 'zs pharma'.
Found 2 results
Redwood City, Calif. – July 29, 2015 – ZS Pharma, Inc. (Nasdaq: ZSPH), today announced that its New Drug Application (NDA) for ZS-9 (sodium zirconium cyclosilicate) for the treatment of hyperkalemia, has been accepted for filing by the United States Food and Drug Administration (FDA). We have been informed that the Prescription Drug User Fee Act (PDUFA) goal date for a decision by the FDA is May 26, 2016.